| 本文已被：浏览 1335次 下载 1059次 |
码上扫一扫！ |
| 细胞因子信号转导抑制分子1在胃癌中的表达及意义 |
| 李顺1,邱娜1,朱乐乐1,何杲1,陈晓凡1,李凤朝2,刘清华3* |
|
|
(1. 徐州医科大学临床医学系, 徐州 221004;
2. 徐州医科大学附属医院病理科, 徐州 221002;
3. 徐州医科大学基础医学院病理学教研室, 徐州 221004
*通信作者) |
|
| 摘要: |
| 目的 分析细胞因子信号转导抑制分子1（SOCS1）在胃癌组织中的表达及其与患者临床病理参数间的关系，探讨其在胃癌患者预后中的意义。方法 收集67例无术前放射治疗和化学治疗史的胃癌患者的胃癌及癌旁组织标本，建立组织芯片，通过免疫组织化学染色SP法检测组织中SOCS1蛋白的表达情况。采用χ2检验分析SOCS1蛋白表达与患者临床病理参数的关系，采用Kaplan-Meier生存曲线和log-rank检验分析SOCS1蛋白表达与患者生存的关系，采用Cox比例风险回归模型分析SOCS1蛋白表达与预后的关系。结果 SOCS1蛋白阳性表达率在胃癌组织中为80.6%（54/67），在癌旁组织中为61.2%（41/67），两组间差异有统计学意义（P<0.05）。SOCS1蛋白表达阳性患者的淋巴结转移率高于阴性表达患者[74.1%（40/54）vs 38.5（5/13），P<0.05]。Kaplan-Meier生存分析结果显示，SOCS1蛋白阳性表达患者的总生存率低于阴性表达患者（P<0.05）。Cox比例风险回归模型分析结果显示，SOCS1蛋白表达和肿瘤TNM分期是胃癌患者的独立预后因素。结论 SOCS1蛋白在胃癌中高表达，检测其表达情况有助于临床判断胃癌患者淋巴结转移及预测预后。 |
| 关键词: 胃肿瘤 细胞因子信号转导蛋白抑制因子 淋巴转移 预后 |
| DOI：10.16781/j.0258-879x.2019.02.0226 |
| 投稿时间：2017-03-15修订日期：2018-06-17 |
| 基金项目:国家级大学生创新创业训练计划（201310313019），江苏省高等学校大学生实践创新训练计划（201310313019Z），徐州医学院院长人才基金（2012KJZ01）. |
|
| Expression and clinical significance of suppressor of cytokine signaling 1 in gastric cancer |
| LI Shun1,QIU Na1,ZHU Le-le1,HE Gao1,CHEN Xiao-fan1,LI Feng-chao2,LIU Qing-hua3* |
(1. College of Clinical Medicine, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China;
2. Department of Pathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, China;
3. Department of Pathology, College of Biomedical Science, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
*Corresponding author) |
| Abstract: |
| Objective To analyze the expression of suppressor of cytokine signaling 1 (SOCS1) in gastric cancer tissues and its relationship with the clinicopathological parameters, and to explore the clinical significance of SOCS1 as the prognostic indicator of gastric cancer patients. Methods Sixty-seven pairs of gastric cancer tissue and adjacent tissue specimens were collected to establish tissue microarray from the gastric cancer patients without preoperative radiotherapy or chemotherapy history, and the expression level of SOCS1 was detected by immunohistochemical SP method. χ2 test was used to analyze the relationship between SOCS1 protein expression and clinicopathological parameters of the patients. Kaplan-Meier survival curve and log-rank test were used to analyze the relationship between SOCS1 protein expression and survival of patients. Cox proportional hazards regression model was used to analyze the relationship between SOCS1 protein expression and prognosis. Results The positive expression rate of SOCS1 was 80.6% (54/67) in gastric cancer tissues and 61.2% (41/67) in adjacent tissues, and the difference was significant (P<0.05). Incidence of lymph node metastasis in the patients with positive expression of SOCS1 was significantly higher than that in the patients with negative expression of SOCS1 (74.1%[40/54] vs 38.5[5/13], P<0.05). Kaplan-Meier survival analysis showed that the total survival rate of the patients with positive expression of SOCS1 was significantly lower than that of the patients with negative expression of SOCS1 (P<0.05). Cox proportional hazards regression model showed that SOCS1 and TNM stage were independent prognostic factors in patients with gastric cancer. Conclusion SOCS1 is highly expressed in gastric cancer, and it may be used as an important indicator for predicting lymph node metastasis and evaluating prognosis of gastric cancer patients. |
| Key words: stomach neoplasms suppressor of cytokine signaling proteins lymphatic metastasis prognosis |
